The landscape of treatment options for Hereditary Orotic Aciduria (HOA) is evolving rapidly, with several promising therapies in various stages of development. As researchers gain a deeper understanding of the underlying genetic mechanisms driving the disorder, novel therapeutic approaches are being explored to address the unmet medical needs of patients with HOA.
Hereditary orotic aciduria is a rare hereditary disease caused by deficiency in the enzyme uridine-5’-monophosphate synthase, which is involved in pyrimidine metabolism. This leads to accumulation of orotic acid in the urine, resulting in vomiting, fatigue, and developmental delay if untreated. Treatment of the condition involves pyrimidine supplementation using natural occurring pyrimidines or its precursors like uridine. The global hereditary orotic aciduria market comprises drugs for ... Read more
The Global Hereditary Orotic Aciduria Market presents a unique landscape of challenges and opportunities for stakeholders in the healthcare sector. With advancements in genetic research and increasing awareness, this market is poised for significant expansion in the coming years.
Global hereditary orotic aciduria market was valued at US$ 357.9 Mn in 2023 and is expected to reach US$ 509.8 Mn by 2031, exhibiting at a compound annual growth rate CAGR of 4.5% from 2024 to 2031 ... Read more
